Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 15

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 15
---
                                                 |

| ● | Higher                                                                                   
 than expected costs of preparing an application for clinical trials and FDA approvals of 
 our product candidates’ development programs.                                            |

| ● | FDA                 
 approval in general |

| ● | Higher                                                                                          
 than expected costs to further develop and scale up manufacturing of our therapeutic candidates 
 through CDMOs (Contract Development and Manufacturing Organizations).                           |

| ● | Competition      
 for our products |

| ● | Our                                                                                            
 ability to achieve milestones under licensing arrangements and the costs involved in enforcing 
 or defending patent claims and other intellectual property rights.                             |

To date, we have financed our operations through a mix of equity investments from private investors, and we expect to continue to utilize such means of financing for the foreseeable future. However, additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms, or at all.

If we raise capital through the sale of equity, or securities convertible into equity, it will result in dilution to our then existing stockholders, which could be significant depending on the price at which we may be able to sell our securities.

If we raise additional capital through the incurrence of indebtedness, we may become subject to covenants restricting our business activities, and holders of debt instruments may have rights and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under debt facilities could divert funds that would otherwise be available to support research and development or commercialization activities. Any debt financing that we obtain in the future could involve substantial restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential sources for such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing.

If we are unable to raise capital when needed on commercially reasonable terms, we could be forced to delay, reduce or eliminate our research and development for our product candidates or any future commercialization efforts or ultimately cease operations. Any of these events could significantly harm our business, financial condition and prospects.

<div align='center'>9</div>

We anticipate that we can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to comply with LipoVation’s contractual obligations under the Yissum License Agreements or other licenses or related agreements to which we may be a party in the future, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles (N